The estimated Net Worth of Edward J Iii Dulac is at least $3.27 Million dollars as of 4 March 2024. Mr. Dulac owns over 2,447 units of Fate Therapeutics Inc stock worth over $393,739 and over the last 4 years he sold FATE stock worth over $2,881,038. In addition, he makes $0 as Chief Financial Officer at Fate Therapeutics Inc.
Sign up
Mr. Dulac FATE stock SEC Form 4 insiders trading
Edward has made over 13 trades of the Fate Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,447 units of FATE stock worth $19,013 on 4 March 2024.
The largest trade he's ever made was selling 19,460 units of Fate Therapeutics Inc stock on 28 September 2021 worth over $1,216,834. On average, Edward trades about 4,057 units every 46 days since 2020. As of 4 March 2024 he still owns at least 101,479 units of Fate Therapeutics Inc stock.
You can see the complete history of Mr. Dulac stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Edward Dulac biography
Edward J. Dulac III serves as Chief Financial Officer of the Company. Prior to joining the Company, Mr. Dulac, age 45, was Vice President of Business Development & Strategy from 2017 to 2020, and held roles of increasing responsibility in business development, portfolio development strategy and commercial planning since 2012, at Celgene Corporation, a biotechnology company acquired by Bristol-Myers Squibb in 2019. From 2007 to 2012, Mr. Dulac was a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers, prior to which he worked in corporate finance at Pfizer Inc. Mr. Dulac received a B.S. in Pharmacy from the University of Pittsburgh and an M.B.A. from the Kelley School of Business at Indiana University.
How old is Edward Dulac?
Edward Dulac is 45, he's been the Chief Financial Officer of Fate Therapeutics Inc since 2020. There are 12 older and 3 younger executives at Fate Therapeutics Inc. The oldest executive at Fate Therapeutics Inc is William Rastetter, 72, who is the Independent Chairman of the Board.
What's Edward Dulac's mailing address?
Edward's mailing address filed with the SEC is C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE, MA, 02139.
Insiders trading at Fate Therapeutics Inc
Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part..., and Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.
What does Fate Therapeutics Inc do?
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
What does Fate Therapeutics Inc's logo look like?
Complete history of Mr. Dulac stock trades at Fate Therapeutics Inc and Intellia Therapeutics Inc
Fate Therapeutics Inc executives and stock owners
Fate Therapeutics Inc executives and other stock owners filed with the SEC include:
-
John Wolchko,
President, Chief Executive Officer, Director -
Bahram Valamehr,
Chief Development Officer -
Cindy Tahl,
General Counsel and Corporate Secretary -
Daniel Shoemaker,
Chief Scientific Officer -
J. Scott Wolchko,
Founder, CEO, Pres & Director -
Dr. Bahram Valamehr Ph.D.,
Chief R&D Officer -
Cindy R. Tahl,
Gen. Counsel & Corp. Sec. -
Karin Jooss,
Independent Director -
Shefali Agarwal,
Director -
William Rastetter,
Independent Chairman of the Board -
Timothy Coughlin,
Independent Director -
John Mendlein,
Independent Vice Chairman of the Board -
Robert Epstein,
Independent Director -
Michael Lee,
Independent Director -
Edward Dulac,
Chief Financial Officer -
Robert Hershberg,
Director -
Renee Leck,
IR Contact Officer -
Yu-Waye Chu,
Vice President - Clinical Development -
Sarah Cooley,
Senior Vice President - Clinical Translation -
Dr. Mark Plavsic D.V.M., Ph.D.,
Chief Technical Officer -
Dr. Yu-Waye Chu M.D.,
Sr. VP of Clinical Devel. -
Jim Beitel M.B.A.,
Sr. VP of Corp. Devel. -
Dr. Wen Bo Wang,
Sr. VP of Technical Operations -
Edward J. Dulac III,
CFO & Principal Accounting Officer -
Mark J Enyedy,
Director -
Stewart Abbot,
Chief Development Officer -
Chris Storgard,
Chief Medical Officer -
Amir Nashat,
Director -
Brian T. Powl,
Chief Commercial Officer -
J Scott Wolchko,
President and CEO -
Group, Llc Green Jeremy Red...,
-
Pratik S Multani,
Chief Medical Officer -
Peter D Flynn,
See remarks -
Christian Weyer,
See remarks -
Venture Fund Vi Lparch Vent...,
-
Venture Partners Vii Lpovp ...,
-
Venture Management Co. V, L...,
-
Robert Nelsen,
Director -
Associates V Lpvenrock Part...,
-
Yuan Xu,
-
Mark Plavsic,
Chief Technical Officer -
Neelufar Mozaffarian,